VERVE THERAPEUTICS INC (VERV) Stock Analyst Ratings
USA - NASDAQ:VERV - US92539P1012 - Common Stock
11.13 USD
+0.03 (+0.27%)
11.2 USD
+0.07 (+0.63%)
ChartMill assigns a Buy % Consensus number of 71% to VERV. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 13.26. This target is 19.14% above the current price.
VERV was analyzed by 14 analysts. The buy percentage consensus is at 71. So analysts seem to be have mildly positive about VERV.
In the last month the buy percentage fell by 13 points. So the trust of analysts is decreasing.
VERV was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-06-27 | BMO Capital | Downgrade | Outperform -> Market Perform |
| 2025-06-18 | LifeSci Capital | Downgrade | Outperform -> Market Perform |
| 2025-06-18 | Jefferies | Downgrade | Buy -> Hold |
| 2025-06-18 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-06-17 | William Blair | Downgrade | Outperform -> Market Perform |
| 2025-06-17 | Canaccord Genuity | Downgrade | Buy -> Hold |
| 2025-04-15 | Cantor Fitzgerald | Upgrade | Neutral -> Overweight |
| 2025-04-15 | Guggenheim | Maintains | Buy -> Buy |
| 2025-04-15 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-04-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-25 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-03-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-04 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-02-28 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-06 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-11-06 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-11-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-12 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-08-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-09 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-05-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-03 | Stifel | Maintains | Buy -> Buy |
| 2024-02-28 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2023-09-13 | Cantor Fitzgerald | Reiterate | Neutral -> Neutral |
| 2023-08-29 | Cantor Fitzgerald | Reiterate | Neutral -> Neutral |
| 2023-08-15 | Guggenheim | Maintains | Buy -> Buy |
| 2023-08-11 | Credit Suisse | Reiterate | Neutral -> Neutral |
| 2023-06-16 | Canaccord Genuity | Reiterate | Buy -> Buy |
| 2023-05-16 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2023-04-13 | Canaccord Genuity | Initiate | Buy |
VERVE THERAPEUTICS INC / VERV FAQ
Can you provide the average price target for VERVE THERAPEUTICS INC stock?
14 analysts have analysed VERV and the average price target is 13.26 USD. This implies a price increase of 19.14% is expected in the next year compared to the current price of 11.13.
Can you provide the consensus rating for VERVE THERAPEUTICS INC stock?
The consensus rating for VERVE THERAPEUTICS INC (VERV) is 71.4286 / 100 . This indicates that analysts generally have a positive outlook on the stock.